MRN:_____

DOB:_____

STANDARD Simponi ARIA ® (golimumab) PLAN OF TREATMENT FOR RHEUMATOLOGY

NOTE: Patient ***may be ineligible*** to receive golimumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new or worsening symptoms of CHF, new-onset or deterioration neurological changes, and/or surgery.

1. Patient Name:_____ Height (inches):_____ Weight (lbs):_____

2. Allergies:_____

3. Diagnosis: *** Please complete the 2nd and 3rd digits to complete the ICD-10 code for billing**

☐ **M05.**_____Rheumatoid Arthritis with Rheumatoid factor ☐ **M06.**_____Rheumatoid Arthritis without Rheumatoid factor

☐ **L40.5**_____Psoriatic Arthropathy ☐ M**45.**_____Ankylosing Spondylitis

☐ Other **ICD-10 Code**:_____ **Diagnosis description:** _____

4. Pre-medications: *Administered 30 minutes prior to infusion as selected:*

****Product information does not suggest premedication and suggest caution with use of Diphenhydramine due to 30-minute infusion time and safety risks with driving.***

a) Acetaminophen: □ 650mgs PO □ 500mgs PO □ 325mgs PO	b) Diphenhydramine: □ 25 mgs PO, □ 50mgs PO, □ 25 mgs IVP, □ 50mgs IVP or c) Alternate oral antihistamine to diphenhydramine: □ Cetirizine 10 mg, □ Loratadine 10 mg, Fexofenadine □ 60mgs or □ 180mgs d) Other: Methylprednisolone □ 40mgs IVP □ 125mgs IVP or other_____mgs IVP Famotidine: □ 20mgs PO, □ 40mgs PO, □ 20mgs IVP, □ 40mgs IVP

Orders:

Extended 30-minute post infusion monitoring for any patient new to therapy for first 3 treatments. Pharmacist to perform clinical drug monitoring. *If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES.*

Dose: Simponi ARIA® (golimumab) 2 mg/kg per 100 ml Sodium Chloride 0.9% IV to infuse over at least 30 minutes

5. Frequency: ☐ Induction orders to be completed at 0 week and 4 weeks, and then every 8 weeks thereafter
☐ Orders every 8 weeks (maintenance).
☐ Special Orders: _____

Lab orders with infusions: _____

6. Physician's Signature:_____/_____ Date: _____

No Stamp Signatures (Dispense as written) (Substitution permitted)

Printed Physician's Name with Credentials:_____ NPI: _____

MRN:_____

DOB:_____

Guidelines for Prescribing Simponi ARIA® (golimumab) for Rheumatology

(Required documentation with all initial referrals)

Patient Name: _____ **Referral Date:**_____

☐ Include signed and completed **Plan of Treatment**.

☐ Include patient demographic information and insurance information. (Copy of insurance cards if available)

☐ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**

- SIMPONI ARIA® is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients
  - Moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate. **If the patient is unable to take methotrexate, then MD must include supporting documentation as to reason/rational.**
  - Active Psoriatic Arthritis (PsA)
  - Active Ankylosing Spondylitis (AS)

☐ If patient is switching biological therapies, then MD must specify wash-out period prior to starting Simponi ARIA® as specified of_____weeks. Last known biological therapy:_____and last date received:_____. (Include copy of last Simponi ARIA® infusion record if available and currently on therapy)

☐ Other as requested: _____

_____

Pre-Screening: (**TB and Hepatitis screening results must be available prior to start of therapy and within last 12 months.)**

☐ **Required TB screening results: PPD or QuantiFERON Gold Test.**
(* If screening results are positive or indeterminate, then a negative CXR result is required.)

☐ **Required Hepatitis screening to include: Hepatitis B Surface Antigen results.**

** Warnings/Precautions: **Serious Infections:** Patient should not have an active ongoing infection, signs or symptoms of malignancy, or invasive fungal infection. **Congestive Heart Failure:** If a decision is made to administer SIMPONI ARIA to RA patients with CHF, these patients should be closely monitored during therapy, and SIMPONI ARIA® should be discontinued if new or worsening symptoms of CHF appear. **Hepatitis B Reactivation:** Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop SIMPONI ARIA and begin anti-viral therapy. Evaluation of immunizations should be completed prior to and live vaccines should not be given before or concurrently with Simponi ARIA ®. See full prescribing information.

Checklist for referrals to AccuRX Infusion Center:

Fax referral to 1-866-990-3192

- Patient demographics – address, phone number, SS#, etc.
- Insurance Information – copy of the card(s) if possible
- Plan of Treatment/Orders
- Most recent physician office notes to include tried and failed therapies – all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs
- Any lab results or other diagnostic procedures to support the diagnosis

AccuRx Infusion Center will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.